Year in Review: Follicular Lymphoma
Studies demonstrating high response rates and manageable safety profiles, along with FDA approvals, have supported bispecific antibodies as promising treatment options for follicular lymphoma. At the start of 2023, a new option became available with the accelerated approval of mosunetuzumab (Lunsumio) late last year. The first-in-class bispecific monoclonal antibody works by inducing CD20-directed CD3 T-cell […]